transcription factors 2 . Promoter activity also can be affected by local and distal regulatory elements 1, 3, 4 . Chemical modifications to DNA and associated histone proteins govern chromatin accessibility, and regulatory elements demonstrate dynamic signatures of these modifications that correlate with their activity in different cell states and types [4] [5] [6] [7] [8] [9] (Table 1) . The causal relationships between histone and DNA modifications and transcription are complex and incompletely understood, and exhaustive mapping of the eukaryotic histone code has only just begun 4, 10, 11 . Coordinated efforts to annotate eukaryotic epigenomes have revealed the complex layer of regulation that orchestrates diverse phenotypes from the same underlying genomic sequence in multicellular organisms 3, 4, 7 . These findings have generated correlations between transcriptional activity and the dynamic modification of DNA and histone subunits 9, 12 . The function of these modifications can be determined targeted transcriptional activation The direct fusion of potent transcriptional effector domains to designed DBDs can induce transcriptional activation when targeted to endogenous genes. Shortly after the modular nature of ZFP recognition of DNA was identified 25 , ZFPs were linked to VP16 (refs. 26,27) to create a programmable transcriptional activator 24, 25 . VP16 is a viral activation domain that recruits Pol II transcriptional machinery 28 . VP64, a tetramer of VP16 domains, has been linked to DBDs to activate coding and noncoding genes via targeting of promoters and regulatory elements [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] . Although VP64 does not directly modify chromatin, it recruits remodeling factors and has been linked to increased chromatin accessibility and to the deposition of activating histone marks, including acetylation of the lysine 27 residue of histone subunit 3 (H3K27ac) and methylation of the lysine 4 residue of histone subunit 3 (H3K4me) 36, 38, 39 . Another commonly used activator is the p65 subunit of the human NF-κB complex 40 , which has been tethered to ZFPs 41 , TALEs 31, 32 and dCas9 (ref. 35) . Gene induction by VP64 and p65 is generally strongest when effector domains are targeted upstream of transcription start sites (TSSs) and in promoter regions 35 , although targeting downstream of TSSs and at distal enhancers can also be effective 36, 37, [42] [43] [44] .
Recruitment of multiple TALE-and dCas9-VP64 fusions to a single target locus is often required to elicit a robust transcriptional response 21, [31] [32] [33] [34] [45] [46] [47] . Recently, next-generation activators have been developed that outperform the original dCas9-VP64 fusion by recruiting multiple effector domains to a single dCas9-gRNA complex 34, 35, 37, [48] [49] [50] . For example, the SunTag system recruits multiple VP64 activators to dCas9, resulting in stronger activation with a single gRNA than achieved with dCas9-VP64 fusions 51 . Repurposing the gRNA as a scaffold for the recruitment of activation domains p65 and HSF1 via MS2-targeting Targeted control over epigenetic regulation is achieved via fusion of programmable DNAbinding domains (DBDs) to epigenome editing effectors. These engineered epigenome editing proteins can be used for basic research, biotechnology and therapeutic applications. DNMT3A, DNMT3B, DNMT3L, DNMT1 (maintenance) [159] [160] [161] TET family 162 , TDG 163 High CpG methylation Repressed promoters, repressed enhancers 4 ; often within transcribed gene bodies 159 DNMT3A, DNMT3B, DNMT3L, DNMT1 (maintenance) [159] [160] [161] TET family 162 , TDG 163 npg review aptamers also improves transcriptional activation 35 . Fusion of VPR (the product of the tandem fusion of VP64, p65 and Rta, a transactivation domain from gammaherpesviruses 52 ) to the C terminus of dCas9 also increases transcriptional activation in human cells compared to dCas9-VP64 (ref. 49) . These improved methods enable the use of single gRNAs to achieve robust activation, potentiating genome-wide gene activation screens 45, 53 .
Further work is required to clarify the differences between these next-generation activators, assess the epigenetic marks indirectly deposited by these domains, and elucidate the mechanisms by which co-recruitment of orthogonal domains synergistically enhances transcription. Epigenetic effectors that directly catalyze covalent modifications to DNA or histones can also activate gene expression. Engineered ZFP-and TALE-based TET and TDG fusions can demethylate CpGs at target promoters, leading to transcriptional induction 43, [54] [55] [56] . Additionally, dCas9, TALEs and ZFPs have been fused to the catalytic core of the p300 histone acetyltransferase to deposit H3K27ac and activate gene expression from promoters and distal enhancers 38 . p300 Core fusions are particularly promising for transcriptional activation, as they do not require multiplexing and can activate distal enhancers that are unresponsive to dCas9-VP64 (ref. 38) . DBD-p300 Core fusions were the first reported targetable histone acetyltransferases, and future engineered activators may include effectors that recruit other histone marks associated with active gene expression, such as H3K4me.
targeted transcriptional repression
Site-specific gene silencing with engineered DBD-repressor fusions offers an alternative to RNAi, which has been limited by 23, 26, 59, 60 . For example, dCas9 targeted to the Nanog enhancer disrupts binding of endogenous activating transcription factors and silences Nanog expression 37 . However, gene repression by steric hindrance alone is often not sufficient for robust silencing. Effectors that recruit endogenous epigenetic modifiers of histone marks and DNA methylation, leading to chromatin condensation, typically generate more potent silencing [61] [62] [63] [64] . The silencing domain most commonly used with DBDs is the Krüppel-associated box (KRAB), a naturally occurring motif in mammalian zinc-finger transcription factors 48, 65, 66 . Localizing KRAB to DNA initiates a heterochromatin-forming complex that includes the histone methyltransferase SETDB1 and the histone deacetylase (HDAC) NuRD complex [67] [68] [69] [70] . In contrast to engineered activator platforms that benefit from multiplexing for potent activation, KRAB fusions do not seem to act synergistically and can readily achieve tenfold or greater repression of endogenous genes with recruitment of a single effector 37, 48, 61, 62 . In addition to being able to silence genes from promoters, KRAB can effectively repress distal and proximal gene regulatory elements including enhancers 64, 71 . Fusions of TALE DBDs to SID4X, the interaction domain of mSin3a, also recruit histone deacetylase activity to silence target genes 66, 72 .
Alternatively, effector domains that directly catalyze repressive DNA methylation or histone modifications can be fused to DBDs to create custom epigenetic silencing proteins. Synthetic ZFPs tethered to DNMT3a catalyze DNA methylation and suppress transcription from endogenous gene promoters 56, [73] [74] [75] [76] . LSD1 has been tethered to TALEs and dCas9 DBDs to remove H3K4me from active enhancers and suppress downstream target expression 64, 77 . A variety of ZFPand TALE-based histone methyltransferase fusions have also been created that repress endogenous gene transcription by depositing H3K9 monomethylation 78 , dimethylation 63, 79, 80 and trimethylation 80 at promoter regions ( Table 2) .
Each type of epigenetic repressor provides unique advantages conferred by its mechanism of action. The KRAB domain acts as a recruiter, and the complex of heterochromatin-modifying enzymes that it localizes to target DNA probably contributes to its versatility and potency for silencing protein-coding genes, noncoding RNA and regulatory elements 37, 48, 61, 66, 71 . For investigations of the roles of specific histone marks or DNA methylation states, the use of enzymatic epigenetic effectors that catalyze a particular type of epigenetic modification may be desired. Lastly, the temporal stability and heritability of silencing are important considerations. Silencing induced by the Kap1 complex associated with the KRAB domain can persist through cell replication 81, 82 , and H3K9 methylation and HP1 localization are properties of constitutive heterochromatin 83 . Silencing with KRAB-and H3K9 methyltransferase-based repressors, however, has been reversible after removal of the DBD-repressor fusion in some studies 48, 80 . Alternatively, targeted DNA methylation marks have the potential to be inherited by daughter cells and persist long term-a benefit for applications in which stable and heritable suppression is desired 73, 76 . An important goal for future work is to generate a better understanding of how the heritability and persistence of gene modulation and epigenetic marks are affected by the duration and magnitude of the activity of the epigenetic effector, the local chromatin environment, the cell type, the presence of endogenous cofactors, and the identity of the epigenetic marks being created.
Eukaryotic cells host a variety of proteins and other molecules with the potential to catalyze epigenetic modification, only a small fraction of which have been used for epigenome engineering applications so far. Generating new active DBD-effector combinations can be challenging, as genetically fusing effectors to synthetic DBDs may affect protein structure and epigenome editing activity. The optimization of linkers for epigenome editing proteins or the development of alternative recruitment strategies could address this issue and lead to an expanded toolbox of novel effector fusions.
specificity of epigenome editing
The rapid and widespread application of designer epigenome editing proteins necessitates further study of the specificity of these tools for binding target sequences, modulating transcription and altering chromatin structure. Genome-wide mapping of DNA binding by chromatin immunoprecipitation followed by sequencing (ChIP-seq) has revealed substantial off-target localization of ZFP, TALE, and dCas9 fusions in many cases 39, 71, [84] [85] [86] [87] [88] . For dCas9, off-target binding correlates with the presence of a 5-to 7-bp protospacer seed sequence followed by a PAM 39, 71, [85] [86] [87] [88] . The functional consequences of these off-target binding events are unclear, as off-target localization does not always result in changes in gene transcription or chromatin accessibility, as measured by RNA sequencing (RNA-seq) and DNase I hypersensitivity sequencing 39, 45, 71 . In fact, analysis of global gene expression via microarray analysis and RNA-seq has shown near-perfect specificity with transcription-modulating proteins 39, 45, 62, 71, 89 . TALE-VP64 and dCas9-VP64 activators have demonstrated high specificity with a robust transcriptional response 32, 35, 39 . Similarly, dCas9-p300 Core fusions have demonstrated highly specific gene activation 38 . dCas9-KRAB repressor fusions do not cause any off-target gene silencing events when targeting a gene reporter 62 and are highly specific with respect to genome-wide gene regulation, DNA binding, creation of targeted H3K9me3 marks and the formation of heterochromatin when targeted to an endogenous enhancer 71 . Furthermore, dCas9-KRAB silencing is highly sensitive to mismatches in the PAM-proximal region of the protospacer 48 .
Small-scale targeted assessments, such as ChIP combined with quantitative PCR for histone modifications, suggest that programmable epigenome editing proteins have limited off-target effects 38, 43, 64, 77 . However, genome-wide studies of histone marks and DNA methylation have been reported for a limited subset of epigenetic effector domains 39, 71, 84 . For example, reports of npg review the distance of silencing activity, spreading of H3K9me3, and chromatin condensation induced by KRAB domains attached to different DBDs vary substantially 68, 71, 81, 82 . The specificity of engineered epigenome editing proteins for alterations of DNA and histone structure is critical to their further application in highthroughput screens, mechanistic studies of epigenome modifications, and guiding cell behavior.
The ability to control the dose of Cas9 expression, implement truncated gRNAs with reduced binding energy, and engineer more stringent requirements for Cas9-PAM interactions has mitigated off-target Cas9 nuclease activity (reviewed in ref. 90 ) and may potentially reduce the likelihood of off-target dCas9-binding events in epigenome editing proteins [91] [92] [93] . Several open-access platforms exist for designing gRNA target sites that are specific genome-wide 91, [94] [95] [96] [97] . An important area of future research will be improving the ability of these tools to predict potential off-target sites, which may be facilitated by the incorporation of experimental observations into existing models 97 .
Conditional gene regulation systems
Temporal control of epigenetic regulation facilitates the dissection of complex gene networks and aids in recapitulating the natural dynamics of gene expression. Chemically inducible promoters, such as the doxycycline-controlled expression system, are widely used for temporal control of transcription 23, 48, 98 . Steroid hormone receptor ligand-binding domains that control protein conformation and cellular trafficking have also been combined with ZFP and TALE activators to achieve conditional transcriptional modulation 99 . Recently, a split dCas9-VP64 system was combined with chemically inducible domains that dimerize and activate gene expression in response to an inducer molecule 93 . For the CRISPR-Cas9 system, inducible gRNA expression may provide more responsive control over transcriptional modulation, as generation and degradation are likely to be faster processes for functional gRNA molecules than for dCas9 protein. For this purpose, methods to adapt gRNA expression to chemically inducible RNA Pol II promoters have been developed using introns and ribozymes 100, 101 .
Light-inducible systems decouple DBDs from the transcriptional regulatory domain and induce their association using exposure to light for spatiotemporal control of gene expression 78, [102] [103] [104] [105] . Light-inducible gene-regulation systems have been used to spatially pattern expression of a transgene [103] [104] [105] , induce expression of endogenous genes in mammalian cells in culture 78, 104, 105 and in vivo 78 , and induce specific epigenetic modifications at target loci 78 . Light-inducible epigenetic regulation is a promising strategy for recapitulating the precisely timed and spatially organized gene expression patterns that emerge during natural tissue development.
modulating regulatory elements and chromatin organization A primary challenge in the study of gene regulation is elucidating the functions of the millions of putative regulatory elements that orchestrate the complex control of tens of thousands of genes in a highly coordinated and context-specific manner 106 . This is a particular challenge because the genes targeted by these elements can vary in number and distance from the regulatory region. It is also a critical area of future research, as the vast majority of genetic variation associated with complex disease lies in these regions 5 . The programmable nature of epigenome editing tools uniquely enables researchers to interrogate regulatory regions and uncover the biological roles of genomic elements in their native genomic context [36] [37] [38] 44, 64, 71, 77 .
Targeting enhancers is an efficient way to modulate multiple genes with a single epigenome-editing protein 38, 71 . Furthermore, regulating genes via their associated enhancers may allow for more effective control over transcription than could be achieved by targeting the promoter alone 36, 64, 107 . The lysine demethylase LSD1 has been coupled with TALEs 77 and dCas9 (ref. 64 ) to silence putative enhancers by removing H3K4me. Loss-of-function studies with dCas9-LSD1 were used to identify novel enhancers involved in embryonic stem cell pluripotency 64 . For gain-offunction studies, dCas9-p300 Core fusions have been shown to activate potent gene transcription from a variety of regulatory elements 38 . Importantly, these studies show that altering specific histone modifications can directly modulate transcription from distal regulatory elements, illustrating how epigenome editing technologies can be used to dissect mechanisms of gene regulation. Future studies combining targeted epigenetic alterations with genome-wide analysis of transcriptional and epigenetic consequences could facilitate the discovery and characterization of novel downstream targets of candidate noncoding genes, enhancers, and insulators.
Engineered epigenome editing proteins can be used to investigate how gene regulation is linked to higher-order chromatin structure. Enhancers activate distal genes by physically interacting with target promoters via a chromatin loop. As an example of how these tools can be used to reorganize chromatin structure, a fusion of an engineered ZFP to the self-association domain of Ldb1 was designed to initiate looping between the globin locus control region and the silenced γ-globin promoter 108 . Targeting of the ZFP-Ldb1 self-association domain fusion to the γ-globin promoter induced recruitment of endogenous Ldb1 located in distal enhancer-associated protein complexes at the globin locus control region. Notably, this led to potent activation of γ-globin and a concomitant reduction in expression of adult β-globin, suggesting that physical rearrangement of chromatin is causal to globin activation 108 . Ldb1 is an erythroid-specific enhancerassociated factor, but generalized strategies for engineering chromatin looping could potentially be developed via the creation of chemically inducible DBD dimers or DBD fusions that modulate CTCF-mediated looping 109 . To better elucidate the role of nuclear positioning in gene regulation, further studies could investigate silencing of gene expression by sequestering the target region in a loop or subnuclear compartment such as the nuclear lamina, or by blocking regulatory elements that participate in looping.
design and modulation of complex gene regulatory networks
Synthetic biology seeks to understand complex gene regulatory relationships by recreating these networks in controlled environments. Synthetic gene promoters offer further flexibility in the design of multicomponent systems with tunable input-output relationships and temporal control 110 . Recently, targeted epigenetic modulators have been used to construct autoregulatory feedback loops, signaling cascades, genetic switches, and Boolean logic systems 59, 100, 111 . Furthermore, genetic circuits have been constructed in eukaryotic cells to model biological phenomena npg review such as synergy, cooperativity, competition, and repressive epigenetic memory 32, 110, 112, 113 .
As understanding of biological systems improves through the de novo construction of synthetic gene regulatory networks, epigenome editing is also enabling multifaceted modulation of endogenous gene regulatory networks. For such applications, orthogonal tools that mediate different epigenome editing activities at distinct loci in cells are needed. As single-component systems, ZFPs and TALEs are inherently orthogonal owing to their unique programmable protein-DNA interactions. In contrast, two distinct dCas9-effector fusions cannot discriminate between coexpressed gRNAs. However, orthogonal Cas9 species can be used to mediate transcriptional activity via unique associated gRNAs and PAM-recognition sites 114, 115 , providing a means to engineer diverse transcriptional behaviors (Fig. 3a) . Although most gene regulation work to date has been done with Streptococcus pyogenes dCas9 fusions 21, [33] [34] [35] 45, 46, 62 , orthogonal dCas9s from Neisseria meningitidis and Staphylococcus aureus have been described for gene editing and regulation applications 64, [114] [115] [116] . Additionally, recent studies have shown that S. pyogenes Cas9 can be re-engineered via directed evolution to recognize alternatives to the canonical 5′-NGG-3′ PAM 117 .
Alternatively, orthogonality can be incorporated directly into the gRNA molecule (Fig. 3b) . Integrating protein-binding hairpin structures into the 3′ stem-loop region of a gRNA can mediate the recruitment of distinct functional effector proteins at individual target loci by association with a single dCas9 species 34, 35, 98 . An improved understanding of the molecular basis of the dCas9-gRNA interaction will enable researchers to design engineered gRNA scaffolds with novel functions 118 . For example, long RNAs have recently been integrated into the gRNA molecule for locusspecific targeting, expanding potential dCas9 effectors to long noncoding RNA, aptamers, and other functional RNA motifs 119 . Conditional expression of gRNAs combined with gRNAspecific effector recruitment would allow for complex programs of gene activation or repression to influence cellular reprogramming or other multifaceted behaviors such as tissue development, cell migration, and inflammatory response. Additionally, a functional Cas9 nuclease fused to effector domains can be used simultaneously for gene editing and gene regulation, depending on the length of the target sequence 120, 121 , which determines the conformational change of the Cas9 enzyme necessary for DNA cleavage 122 . This approach may be used to devise even more complex cell engineering strategies that combine changes to the genome sequence and gene expression.
high-throughput screens with epigenome editing proteins
Forward genetic screens with libraries of targeted epigenome editing proteins can be used to reveal as yet unknown upstream regulators of differentiation programs, critical members of signaling pathways, or genes that become misregulated in disease progression. Highly flexible, programmable platforms have led to the development of libraries of DBDs to target all potential DNA sequences in a given genome 35, 48, 58, 123, 124 . The CRISPRCas9 system is particularly well suited to pooled screening approaches because targeting is based on oligonucleotides, allowing for commercial synthesis of custom libraries and recovery of selected library members by next-generation sequencing approaches 35, 48, 58 . gRNA libraries have already been designed to activate or repress all coding genes in the human genome 35, 48 , and custom libraries can be obtained from commercial vendors. For gain-of-function screens, second-generation dCas9-based activator systems have been developed to ensure a robust increase in gene expression with a single gRNA 35, 48 . Alternatively, dCas9-KRAB repressors directed by a single gRNA library have been used for genome-wide silencing screens 48 .
These seminal studies provide optimized guidelines for designing gRNA libraries, although recommendations may evolve as future studies extend screening strategies to different genomic targets, epigenetic effectors, and cell types. A better fundamental understanding of the factors that determine optimal interactions of gRNAs with their genomic targets will also advance these methods. For VP64-based dCas9 effectors, gRNA targets were designed in the region approximately -400 to +1 bp from the target TSS 35, 48 . For dCas9-KRAB, gRNA targets covered the region approximately -50 to +300 bp from the TSS 48 . Selecting gRNAs that are highly specific is important when designing libraries, as off-target effects can convolute the interpretation of screens. However, this can be largely addressed by the incorporation of redundancy into gRNA libraries, with coverage of up to 10 gRNAs per TSS 35, 48 .
Robust delivery methods are required to ensure complete library coverage in pooled-library screens. Lentiviral gene delivery of gRNAs is particularly advantageous because the delivered genes are integrated into the host cell's genome, providing stable expression and a means to track delivered gRNAs through cell progeny 35, 48 . Viral production is also highly scalable, and the multiplicity of infection can be optimized for complete coverage of the gRNA library at approximately a single gRNA per cell to minimize interactions between gRNAs and to facilitate isolation of individual gene targets. (a) dCas9 orthologues with distinct PAM requirements can be adapted from different host species or engineered via directed evolution. With unique gRNAs and PAM recognition sites, dCas9 orthologue fusions can be used to effect distinct gene regulation events at multiple targets in a single host genome simultaneously. (b) Alternatively, complex gene regulation events can be coordinated via direct recruitment of epigenetic effectors to the gRNA molecule. Protein-binding motifs and long noncoding RNAs (lncRNAs) can be incorporated directly in the stem-loop structure of the gRNA. npg review Fluorescence-activated cell sorting, drug-based selection, and competitive growth are all potential strategies for enriching gene targets of interest in a library screen. In studies involving selection for regulation of a gene product, screening can be achieved by a reporter system in which expression of a fluorescent protein or antibiotic resistance gene is contingent on modulation of the target gene. Response to drug treatment is a phenotype that is particularly conducive to screening, and it has been used to study mechanisms of antibiotic resistance, drug sensitivity, and escape mechanisms of cancer cells 35, 48 .
Genome-scale libraries with epigenome editing proteins have thus far focused on protein-coding genes, but high-throughput screening approaches can be envisioned that could target other types of genomic element spaces, including enhancers, insulators and noncoding RNA. For instance, dCas9 fusions to p300 Core for activation and to LSD1 for repression may be appropriate for screening the activity of putative enhancers. Such future efforts would benefit from publicly available data on genome-wide epigenetic marks 4 that could be used to customize libraries to the epigenetic state of the cell and phenotype of interest.
Guiding cellular reprogramming
A common strategy for directing cellular reprogramming is the ectopic expression of fate-specifying master regulatory transcription factors 125 . The acquisition of stably reprogrammed cells is contingent on the silencing of exogenously delivered master transcription factors and the concurrent activation of endogenous transcription factors through positive feedback networks. Thus the epigenetic landscape of the starting cell type can determine the cell's permissiveness to reprogramming by exogenous factors [126] [127] [128] . Customizable epigenome editing proteins have recently been used to address some of the intrinsic limitations of exogenous transcription factors with respect to direct cell reprogramming. Using TALE-based transcription factors targeted to the distal enhancer of Oct4 (Pou5f1) in concert with SOX2, KLF4 and C-MYC transgenes, Gao et al. 36 reprogrammed mouse embryonic fibroblasts to induced pluripotent stem cells. Compared to delivery of the OCT4 transgene, targeted activation of endogenous Oct4 induced rapid chromatin remodeling that more closely resembled the epigenetic landscape of the native Oct4 locus in mouse embryonic stem cells. This work demonstrated the value of targeting enhancers to regulate gene expression and facilitate epigenetic remodeling for cell reprogramming. A similar approach could be used to assess the importance of putative enhancers in reactivating cell type-specific gene regulatory networks for cellular reprogramming applications or to interrogate residual or aberrant 'epigenetic memory' observed in reprogrammed cells 129, 130 .
Recent improvements made to CRISPR-Cas9-based transcriptional activators have also been implemented for cellular reprogramming. Targeting of dCas9 fused to two VP64 effectors to Myod1 induced the transdifferentiation of mouse embryonic fibroblasts to skeletal myocytes with an efficiency comparable to that achieved through the overexpression of MYOD1 cDNA 50 . Direct differentiation of human induced pluripotent stem cells into induced neurons has also been demonstrated with one of the next-generation dCas9-based activators, dCas9-VPR 49 . Compared to the first-generation dCas9-VP64 activator, dCas9-VPR achieved higher levels of gene induction, which enabled efficient generation of the neuronal cells.
These proof-of-principle examples demonstrate the feasibility and potential advantages of using targeted epigenome editing proteins for cellular reprogramming. Future work may use these programmable transcription factors in reprogramming applications that require multiplexed gene activation and repression. Furthermore, genome-wide interrogation of noncoding transcripts and gene regulatory elements could reveal factors that, when modulated, improve the kinetics, efficiency, and fidelity of reprogramming.
harnessing epigenetic regulation to treat disease Aberrant gene regulation is often associated with pathological states, either as a symptom or as a cause of underlying disease 131 . Site-specific epigenome editing provides the opportunity to study the contributions of gene regulation to disease and is an exciting potential avenue for treatment.
Targeted activation of compensatory genes can mitigate the symptoms of diseases that have no cure. For instance, engineered activators can induce the expression of developmentally silenced fetal γ-globin and counteract the loss of functional β-globin in sickle cell anemia and β-thalassemia 45, 132, 133 . ZFP-based activators targeted to glial cell line-derived neurotrophic factor (GDNF) have shown promise in rat models for protecting against neural damage as a potential treatment for neurodegeneration associated with Parkinson's disease. Laganiere et al. 134 hypothesized that endogenous gene activation limited GDNF expression to physiological levels, thereby potentially avoiding the toxic side effects observed in ectopic GDNF treatments. Transcriptional modulation strategies can also generate protective effects for regenerative medicine applications. The activation of endogenous vascular endothelial growth factor (VEGF) with engineered ZFPs has been proposed to generate neovasculature in subjects with diabetic neuropathy and peripheral arterial disease, as well as to enhance wound healing 135, 136 . Targeting the VEGF promoter with engineered activators activates all VEGF isoforms, which can result in more mature vasculature formation compared to that achieved via exogenous delivery of a single VEGF isoform 135 . Similarly, engineered ZFP-p65 fusions upregulate pigment epitheliumderived factor and prevent neovascularization in mouse models, suggesting a potential anti-angiogenic treatment for choroidal neovascularization such as that seen in acute macular degeneration 137 . Finally, targeted activation of the aberrantly silenced frataxin gene with TALE-VP64 fusions is being explored to treat Friedreich's ataxia 138 .
Targeted repressors can also suppress detrimental gene products associated with disease progression. Engineered ZFP repressors have been designed to silence oncogenes and have been effective at slowing the growth of cancer cells in mouse models 74, 139 . Synthetic ZFP repressors were also engineered to selectively silence mutant Htt in a mouse model of Huntington's disease 61 . In this study, several ZFP lengths were tested to develop a repressor with specific activity at the longer CAG repeats found in disease-causing mutant Htt alleles. This strategy may also be applicable for treating other gain-of-function genetic diseases, such as fragile X syndrome and myotonic dystrophy, and was recently evaluated in cells from individuals with npg review facioscapulohumeral muscular dystrophy 140 . Pharmacologic modulation of DNA methylation and histone modification has shown preclinical promise for treating tumor progression and neurodegenerative disorders such as Alzheimer's, Parkinson's and Huntington's disease [141] [142] [143] . However, the small-molecule drugs used in these therapies typically act by broadly inhibiting the enzymatic activity of epigenetic effectors, and doses are often limited by toxicity after systemic administration. Programmable epigenetic modification with designer DBDs could potentiate targeted therapy by treating the specific histone and DNA methylation marks that contribute to the progression of such diseases.
Although programmable gene regulation has engendered innovative therapeutic strategies in preclinical studies, barriers to clinical translation remain. A primary challenge is the development of safe and efficient delivery methods 144 . Adeno-associated virus (AAV) is being widely explored in gene therapy in vivo studies and clinical trials, and an AAV product has been approved for clinical use in Europe. AAV delivery of ZFP-and TALE-based transcriptional regulators has demonstrated promising preclinical results in animal models of Huntington's and Parkinson's disease 61, 134 . The recent development of smaller Cas9 systems that are compatible with AAV is a major advance in the development of CRISPR-Cas9-based gene therapy 115 .
Another concern for clinical translation is the potential immunogenicity of engineered epigenome editing proteins. ZFPs, which are based on a protein motif commonly found in human transcription factors, have been well tolerated in in vivo studies, but the potential immunogenicity of TALE and dCas9 DBDs, which are not of mammalian origin, has yet to be explored. The addition of effector domains that are derived from non-mammalian systems, such as VP64, may exacerbate any potential immunogenicity. Furthermore, the introduction of ectopic small RNAs for directing dCas9-based factors has the potential to incite innate immune responses, although they can be mitigated through chemical modification of the delivered gRNAs 145, 146 . Therefore, further work to improve delivery methods and characterize immune responses to engineered epigenome editing proteins is needed before these technologies can be applied clinically.
Conclusions
The simplicity and scalability of the CRISPR-Cas9 system have facilitated its widespread adaptation for targeted epigenetic regulation. Nonetheless, several epigenome editing functions have thus far only been demonstrated with ZFP-and TALEbased platforms. Furthermore, strategies for in vivo delivery of CRISPR-Cas9-based epigenome editing tools have yet to be established. Thus users of the technologies need to balance the ease of use of CRISPR-dCas9 with the validated efficacy of other tools when choosing a platform for a specific application. Custom epigenome editing tools have the potential to become standard for probing interactions among specific chromatin modifications, gene expression and cellular phenotype, but this will require the continued incorporation of new functions into DNA-targeting platforms for catalyzing specific epigenetic marks. 
